Westpac Banking Corp raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 334,939 shares of the biopharmaceutical company’s stock after buying an additional 32,361 shares during the period. Westpac Banking Corp’s holdings in Gilead Sciences were worth $25,798,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Numeric Investors LLC raised its stake in Gilead Sciences by 173.5% in the fourth quarter. Numeric Investors LLC now owns 2,820,505 shares of the biopharmaceutical company’s stock valued at $201,976,000 after buying an additional 1,789,101 shares during the last quarter. Advantage Investment Management LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at $199,000. Thrivent Financial for Lutherans increased its position in shares of Gilead Sciences by 2.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,263,089 shares of the biopharmaceutical company’s stock valued at $162,061,000 after buying an additional 56,110 shares during the period. IFM Investors Pty Ltd purchased a new position in shares of Gilead Sciences during the fourth quarter valued at $1,213,000. Finally, Wall Street Access Asset Management LLC increased its position in shares of Gilead Sciences by 2.9% in the fourth quarter. Wall Street Access Asset Management LLC now owns 3,765 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 107 shares during the period. 74.02% of the stock is owned by institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) opened at 72.11 on Friday. The company has a market cap of $94.17 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21. The stock has a 50 day moving average of $72.61 and a 200-day moving average of $68.83. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.08 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.88%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.
Several research analysts have recently weighed in on the stock. Jefferies Group LLC restated a “hold” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 11th. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price objective on the stock. in a research note on Tuesday, April 25th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 3rd. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, BMO Capital Markets reissued a “hold” rating and set a $76.00 target price (up from $75.00) on shares of Gilead Sciences in a report on Wednesday, May 3rd. Twelve equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $80.31.
In other Gilead Sciences news, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction on Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock worth $15,223,184 in the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
